We have developed two clinical-stage therapeutic candidates for the treatment of chronic HBV, and are advancing a development candidate for the treatment of high-recurrence genital herpes as well as research programs focused on the discovery of additional novel antiviral mechanisms for HBV and other viral diseases.
A pipeline strategy designed to free HBV patients from lifelong therapy and target other serious viral diseases
In our relentless pursuit to discover novel antivirals to treat serious viral diseases and to bring finite and curative treatments to HBV patients, our pipeline is focused on the following areas:
- Long-acting helicase inhibitor for high-recurrence genital herpes caused by herpes simplex virus type 2 (HSV-2)
- Pan-herpes polymerase inhibitor (NNPI) for transplant-associated infections
- Novel, bioavailable small molecule inhibitors of HBV and HDV viral entry that potently block infection of hepatocytes for both viruses
- Novel, bioavailable, liver-focused small molecule agonists of the interferon pathway that are able to activate antiviral cellular responses as well as engage the innate and adaptive immune systems
- Potent, next generation core inhibitors designed to maximally block the formation of new cccDNA
Research programs advancing new small molecule compounds with novel targets and mechanisms
Our research team is focused on proprietary research to discover and develop novel antivirals to treat serious viral diseases. We have announced our first development candidate from our herpesvirus research programs, ABI-5366, a long-acting helicase inhibitor of HSV-2 for patients with high-recurrence genital herpes, and are also progressing a research program for a pan-herpes NNPI for transplant-associated viral infections.
In HBV/HDV, we are currently advancing an early-stage program evaluating a novel small molecule approach to inhibit viral entry for HBV and hepatitis delta virus (HDV), which is estimated to impact approximately 4.5 percent of those chronically infected with HBV – approximately 12 million people globally. We are also advancing our novel orally-bioavailable interferon-α receptor (IFNAR) agonist program that is designed to selectively activate the interferon-α pathway in the liver while reducing systemic exposure to improve tolerability.
Potent next generation core inhibitors
We have two potent, next generation CI product candidates, ABI-4334 (4334) and ABI-H3733 (3733), both optimized for significantly increased potency against cccDNA formation and new virus production versus first-generation core inhibitors. 3733 has completed dosing in a Phase 1b clinical study, and 4334 has completed dosing in a Phase 1a clinical study. We are evaluating partnering options for our core inhibitor portfolio for further clinical development.
More information about our clinical trials can be found at www.clinicaltrials.gov.